Review of the efficacy and safety of PCSK9 inhibitors in the therapy of lipid metabolism disorders

Lipid metabolism disorder with a predominance of very-low-density lipoproteins (VLDL), triglycerides (TG), and cholesterol (CS) in the blood plasma contributes to the development of atherosclerotic diseases, which to date remain the main cause of death among the population, ranking first among all causes of death in the world and claiming the lives of 4 million Earth inhabitants every year. In this regard, there is a need to search for drugs that reduce the level of cholesterol, triglycerides, and VLDL in blood plasma. Such a group of drugs is PCSK9 inhibitors. Purpose of the study: to evaluate the efficacy and safety of the new class of lipid-lowering drugs — PCSK9 inhibitors.